Black Diamond Therapeutics (BDTX) director awarded 40,000 stock options at $1.71
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Black Diamond Therapeutics director Samarth Kulkarni received a grant of stock options covering 40,000 shares of common stock. These options have an exercise price of $1.71 per share and are held directly in his name.
The options vest and become exercisable in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, as long as he continues to serve through that vesting date. After this grant, he holds options to acquire 40,000 shares, and there are no open-market purchases or sales reported in this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Kulkarni Samarth
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 40,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 40,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 40,000 shares
Exercise price: $1.71 per share
Expiration date: June 25, 2036
+2 more
5 metrics
Options granted
40,000 shares
Stock Option (Right to Buy) grant to director
Exercise price
$1.71 per share
Exercise price of granted stock options
Expiration date
June 25, 2036
Option term end date
Vesting date trigger
June 26, 2027
Earlier of this date or next annual meeting
Options after transaction
40,000 shares
Total options held following this grant
Key Terms
Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "1.7100" per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares subject to this option shall vest and become exercisable in full"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting of stockholders financial
"the Issuer's next annual meeting of stockholders"
expiration date financial
"expiration_date: "2036-06-25T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What did Black Diamond Therapeutics (BDTX) director Samarth Kulkarni report on this Form 4?
Director Samarth Kulkarni reported receiving a grant of stock options for 40,000 shares of Black Diamond Therapeutics common stock at an exercise price of $1.71 per share, vesting based on future service and corporate meeting timing.
How many Black Diamond Therapeutics (BDTX) options did Samarth Kulkarni receive and at what price?
Samarth Kulkarni received stock options covering 40,000 shares of Black Diamond Therapeutics common stock with an exercise price of $1.71 per share. These options give him the right, but not the obligation, to buy shares at that price once vested.
When do Samarth Kulkarni’s new BDTX stock options vest?
Kulkarni’s options vest and become exercisable in full on the earlier of June 26, 2027 or Black Diamond Therapeutics’ next annual meeting of stockholders, provided he continues to serve the company through the applicable vesting date.
Does this Black Diamond Therapeutics Form 4 show any open-market buying or selling by Samarth Kulkarni?
The Form 4 does not show any open-market purchases or sales. It reports only a grant of stock options as compensation, meaning no shares were bought or sold in the market as part of this specific filing.